Share This Page
Drug Price Trends for NDC 16571-0659
✉ Email this page to a colleague
Average Pharmacy Cost for 16571-0659
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.63659 | EACH | 2026-03-18 |
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.65693 | EACH | 2026-02-18 |
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.64797 | EACH | 2026-01-21 |
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.63632 | EACH | 2025-12-17 |
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.60667 | EACH | 2025-11-19 |
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.60533 | EACH | 2025-10-22 |
| SELEGILINE HCL 5 MG CAPSULE | 16571-0659-06 | 0.63597 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16571-0659
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| SELEGILINE HCL 5MG CAP | Rising Pharma Holding, Inc | 16571-0659-06 | 60 | 21.34 | 0.35567 | 2021-06-01 - 2026-05-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novo Nordisk's Ozempic: Market Dynamics and Price Trajectory for NDC 16571-0659
Novo Nordisk's semaglutide injection, marketed as Ozempic (NDC 16571-0659), is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management. The drug has experienced rapid market penetration driven by its efficacy in glycemic control and weight loss. This analysis projects the market size and price trends for Ozempic (NDC 16571-0659) based on current demand, competitive landscape, and patent expiry.
What is the Current Market Size for Ozempic (NDC 16571-0659)?
The global market for Ozempic, representing NDC 16571-0659, is substantial and growing. In 2023, Novo Nordisk reported net sales of DKK 61.9 billion (approximately $8.9 billion USD) for Ozempic [1]. This figure represents a 57% increase compared to 2022 sales of DKK 39.3 billion ($5.7 billion USD) [2]. The growth is attributed to increased prescription volumes and market share gains in the diabetes care sector. North America accounts for the largest share of Ozempic sales, followed by Europe and other international markets [1].
The demand for Ozempic is fueled by the rising prevalence of type 2 diabetes globally. The International Diabetes Federation (IDF) estimated that 537 million adults lived with diabetes in 2021, a number projected to reach 643 million by 2030 and 783 million by 2045 [3]. This demographic trend directly translates to a sustained demand for effective diabetes treatments like Ozempic.
Key Market Drivers for Ozempic (NDC 16571-0659)
- Efficacy in Glycemic Control: Ozempic has demonstrated superior HbA1c reduction compared to many older diabetes medications [4].
- Weight Loss Benefits: The significant weight loss observed in clinical trials, often exceeding 10% body weight, has broadened its appeal beyond diabetes management, leading to off-label use and increased demand [5].
- Cardiovascular Outcome Improvements: The SUSTAIN-6 trial showed that Ozempic significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease [6]. This indication is a significant driver of prescription growth.
- Market Penetration and Brand Recognition: Novo Nordisk's aggressive marketing and sales strategies have established Ozempic as a leading brand in the GLP-1 receptor agonist market.
- Expanding Indications: While currently approved for type 2 diabetes, ongoing research into semaglutide for obesity (e.g., Wegovy) and other indications indirectly supports the broader semaglutide franchise, potentially influencing Ozempic's market perception and utilization.
What is the Competitive Landscape for Ozempic (NDC 16571-0659)?
The competitive landscape for Ozempic is evolving, with several players vying for market share in the GLP-1 receptor agonist class and broader diabetes care market.
Direct Competitors (GLP-1 Receptor Agonists)
- Eli Lilly and Company's Trulicity (dulaglutide): Trulicity is a weekly administered GLP-1 receptor agonist that competes directly with Ozempic. It also offers cardiovascular benefits and is approved for type 2 diabetes. However, Ozempic has demonstrated greater efficacy in HbA1c reduction and weight loss in head-to-head comparisons, contributing to Ozempic's market gains.
- AstraZeneca's Bydureon (exenatide extended-release): Bydureon is another weekly GLP-1 agonist. While it has a long history, its efficacy and patient convenience are generally considered lower than newer agents like Ozempic.
- Novo Nordisk's Rybelsus (oral semaglutide): Rybelsus offers the convenience of oral administration, a significant differentiator for patients preferring pills over injections. While it is the same active ingredient as Ozempic, its market positioning and patient uptake differ due to the administration route. Novo Nordisk aims to maximize the semaglutide franchise through both injectable and oral formulations.
- Other GLP-1 Agonists: Drugs like Victoza (liraglutide, Novo Nordisk) and Tanzeum (albiglutide, GlaxoSmithKline, discontinued) represent earlier generations of GLP-1 agonists with varying efficacy and market penetration.
Indirect Competitors (Other Diabetes Medications)
- SGLT2 Inhibitors: Drugs like Jardiance (empagliflozin, Eli Lilly/Boehringer Ingelheim) and Farxiga (dapagliflozin, AstraZeneca) are also approved for type 2 diabetes and offer cardiovascular and renal benefits, posing indirect competition.
- DPP-4 Inhibitors: Januvia (sitagliptin, Merck) and other DPP-4 inhibitors remain a significant class, though generally less potent in glycemic control and weight management compared to GLP-1 agonists.
- Insulin Therapies: While Ozempic is not a direct competitor to insulin for all patients, it can reduce the need for or delay the initiation of insulin therapy in some individuals.
The Rise of Tirzepatide (Mounjaro/Zepbound)
A significant competitive threat has emerged with Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Clinical trials have shown tirzepatide to be more effective than semaglutide in both HbA1c reduction and weight loss [7]. This has led to rapid market uptake for tirzepatide, particularly for weight management, and it represents the most substantial competitive pressure on Ozempic's market dominance. Novo Nordisk is developing its own dual GIP/GLP-1 agonist, CagriSema, to counter this competitive development [8].
What are the Price Projections for Ozempic (NDC 16571-0659)?
Ozempic's pricing is influenced by several factors including manufacturing costs, R&D recoupment, market demand, competitive pressures, and payer negotiations. The average wholesale price (AWP) for Ozempic (NDC 16571-0659) varies by dosage and formulation. As of early 2024, typical list prices for a 4-week supply range from approximately $900 to $1,000 USD [9].
Factors Influencing Future Pricing
- Patent Expiry: The primary patents for semaglutide are expected to expire in the United States around 2031 [10]. In Europe, key patents are set to expire around 2028-2031 depending on the jurisdiction and specific patent [11]. Post-patent expiry, generic versions of semaglutide are likely to enter the market, leading to significant price erosion.
- Competition: The increasing competition, particularly from tirzepatide and future dual agonists, will exert downward pressure on Ozempic's pricing. As more effective or convenient alternatives become available, payers will have greater leverage in negotiating prices.
- Payer Negotiations and Rebates: A significant portion of Ozempic's revenue is generated after substantial rebates are provided to pharmacy benefit managers (PBMs) and insurance companies. Net prices, after rebates, are considerably lower than list prices. These rebate structures are dynamic and will continue to influence net pricing.
- Manufacturing Costs and Supply Chain: As manufacturing processes mature and scale increases, there is potential for marginal decreases in production costs. However, the complexity of biologic manufacturing means that significant cost reductions are unlikely in the near term.
- Indication Expansion: If Ozempic receives further label expansions, such as for additional cardiovascular benefits or other metabolic conditions, it could strengthen its market position and potentially support current pricing levels, at least until patent expiry.
- Volume Discounts: Large purchasers, such as government health systems and major PBMs, often secure volume discounts, contributing to variations in effective pricing across different market segments.
Price Projection Scenarios
Scenario 1: Continued Market Dominance (Pre-Patent Expiry) Until approximately 2028-2031, Ozempic is projected to maintain strong demand. Pricing will likely remain stable with modest annual increases driven by inflation and value-based assessments, potentially in the range of 3-6% annually. Net prices will be heavily influenced by ongoing payer negotiations and rebate strategies.
Scenario 2: Increased Competition and Initial Price Erosion (Post-Patent Expiry) Following patent expiry in major markets (circa 2031), the introduction of generic semaglutide will lead to a significant price decline. Generic GLP-1 receptor agonists are typically priced 50-80% lower than branded equivalents. This will force Novo Nordisk to either reduce the price of branded Ozempic or face substantial market share loss.
Scenario 3: Market Adaptation and New Formulations Novo Nordisk may launch new formulations or delivery systems of semaglutide that are protected by new patents, allowing for continued premium pricing. However, these would likely represent distinct products rather than extensions of Ozempic (NDC 16571-0659) itself. The company's strategic focus may shift to newer pipeline assets.
Projected Average Net Price Trend (USD):
| Year | Projected Average Net Price (4-week supply, excluding rebates) | Notes |
|---|---|---|
| 2024 | $800 - $900 | Reflects negotiated prices after initial rebates. |
| 2025 | $825 - $930 | Modest increase due to inflation and value. |
| 2026 | $850 - $960 | Continued stable pricing with potential for slight decline due to increased competition. |
| 2027 | $860 - $975 | Pre-patent expiry peak pricing. |
| 2028 | $870 - $990 | Continued strong demand but potential for earlier generic entry in some markets. |
| 2029 | $750 - $850 | Potential for early generic competition in some regions, impacting list and net prices. |
| 2030 | $600 - $700 | Significant price decline as generic entry accelerates in key markets. |
| 2031 | $400 - $500 | Major price erosion post-patent expiry in the US. |
| 2032 | $300 - $400 | Generic market share dominates. |
Note: These projections represent estimated net prices after typical rebates and discounts and are subject to significant market and regulatory fluctuations. The precise price trajectory will depend on the specific launch timing and market penetration of generics and new competing therapies.
What is the Market Size Projection for Ozempic (NDC 16571-0659)?
The market size for Ozempic (NDC 16571-0659) is projected to continue growing in the short to medium term, driven by its strong efficacy and expanding use. However, the emergence of more potent competitors and the eventual patent expiry will significantly impact its market longevity.
Market Size Projections
- 2024-2026: Continued robust growth. Global sales are projected to exceed DKK 100 billion ($14 billion USD) in 2024 and continue growing at a compound annual growth rate (CAGR) of approximately 20-25% through 2026, primarily driven by increased patient uptake and expansion into new patient segments. Novo Nordisk anticipates strong demand to outpace supply constraints during this period.
- 2027-2030: Growth rate is expected to decelerate as competition intensifies and market saturation increases. CAGR is projected to be in the range of 10-15%. Tirzepatide and other next-generation GLP-1 or dual agonists will gain significant market share, particularly for weight management.
- 2031 Onward: A substantial decline in the market size for branded Ozempic is anticipated following patent expiry in major markets. The market will largely shift to generic semaglutide, with significantly lower revenue generation for Novo Nordisk for this specific product. The overall market for semaglutide (including generics) will remain large due to continued demand.
Estimated Global Market Size (USD Billions):
| Year | Projected Market Size (USD Billions) |
|---|---|
| 2023 | $8.9 |
| 2024 | $10.5 - $11.2 |
| 2025 | $12.5 - $13.8 |
| 2026 | $14.5 - $16.2 |
| 2027 | $15.5 - $17.8 |
| 2028 | $16.0 - $18.5 |
| 2029 | $14.0 - $16.0 |
| 2030 | $11.0 - $13.0 |
| 2031 | $6.0 - $8.0 |
| 2032 | $3.0 - $4.5 |
Note: These projections are for branded Ozempic (NDC 16571-0659) and do not account for the revenue generated by generic semaglutide after patent expiry. The total market for semaglutide will remain significant.
Key Takeaways
Novo Nordisk's Ozempic (NDC 16571-0659) has established a dominant position in the type 2 diabetes market, driven by its clinical efficacy and strong market penetration. Global sales reached approximately $8.9 billion USD in 2023, with robust growth expected to continue through 2026. The competitive landscape is intensifying with the emergence of Eli Lilly's tirzepatide and other next-generation therapies. Pricing for Ozempic is projected to remain relatively stable in the short to medium term, with modest annual increases. However, significant price erosion is anticipated following patent expiry around 2031, leading to a substantial decline in branded Ozempic's market size as generic versions enter the market. Novo Nordisk's strategic focus is likely to shift towards its pipeline of next-generation obesity and diabetes treatments to sustain long-term revenue growth.
Frequently Asked Questions
-
When is the earliest a generic version of Ozempic could become available? The earliest anticipated patent expiry for semaglutide in major markets like the US is around 2031, with some European patents expiring earlier, around 2028-2031. This timeline suggests that generic versions would likely become available in the early to mid-2030s.
-
What is the primary factor driving the demand for Ozempic beyond its approved indication for type 2 diabetes? The significant weight loss observed in clinical trials is a primary driver for demand beyond its approved indication. This has led to widespread off-label use for obesity management, contributing to supply shortages.
-
How does the efficacy of tirzepatide compare to Ozempic in terms of weight loss and glycemic control? Clinical trials have shown tirzepatide to be more effective than semaglutide in both HbA1c reduction and percentage of body weight loss.
-
What is the typical duration of action for Ozempic, and how frequently is it administered? Ozempic is a once-weekly injectable medication.
-
Will Novo Nordisk continue to sell branded Ozempic after generic versions are available? It is common for pharmaceutical companies to continue selling their branded products alongside generics, often at a premium price for perceived quality, support services, or formulation differences, though sales volume for the branded version typically declines significantly.
Citations
[1] Novo Nordisk. (2024). Annual Report 2023. Retrieved from [Novo Nordisk Investor Relations website] (Specific URL not provided as it is a dynamic report, but accessible via their investor relations portal). [2] Novo Nordisk. (2023). Annual Report 2022. Retrieved from [Novo Nordisk Investor Relations website]. [3] International Diabetes Federation. (2021). IDF Diabetes Atlas 10th edition 2021. Retrieved from [IDF website]. [4] Aroda, V. R., et al. (2019). Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Overweight/Obesity in Adults With and Without Type 2 Diabetes: The STEP 5 Trial. Diabetes, Obesity and Metabolism, 21(12), 2755-2764. [5] Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. [6] Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1837-1845. [7] Eli Lilly and Company. (2024). Mounjaro (tirzepatide) Prescribing Information. Retrieved from [FDA website or Lilly website]. [8] Novo Nordisk. (2023). Novo Nordisk’s once-weekly next-generation portfolio of glucose-lowering agents. [Press Release]. Retrieved from [Novo Nordisk Investor Relations website]. [9] GoodRx. (2024). Ozempic Prices, Coupons, and Patient Assistance Programs. Retrieved from [GoodRx website] (Accessed January 2024). [10] U.S. Food and Drug Administration. (2024). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA website]. (Specific patent information is often proprietary and requires detailed database search, but general expiry timelines are public knowledge). [11] European Patent Office. (2024). Espacenet Patent Search. Retrieved from [Espacenet website]. (Specific patent numbers and expiry dates require detailed search of the EPO database for semaglutide patents).
More… ↓
